

CORRIGENDUM

In the article by Kempton et al,¹ couple of errors were identified.

Reference 14 was listed incorrectly. The correct reference has been mentioned below.

Theodore-Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A. Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. *Patient Prefer Adherence*. 2016;10:1767–1776.

The expansion of RASQ was mentioned as “Rituximab Administration **Symptom** Questionnaire”; however, the correct expansion is “Rituximab Administration **Satisfaction** Questionnaire”.

REFERENCE

1. Kempton C, Trask P, Parnes A, et al. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. *Haemophilia*. 2021;27:221-228.